[Objectives]This study aimed to observe the clinical efficacy of sedative cataplasm in the treatment of insomnia patients with sub-health.[Methods]A total of 90 insomnia patients with sub-health were randomly and even...[Objectives]This study aimed to observe the clinical efficacy of sedative cataplasm in the treatment of insomnia patients with sub-health.[Methods]A total of 90 insomnia patients with sub-health were randomly and evenly divided into treatment group and control group.The patients in the control group were given Bozi Yangxin pills orally,and those in the treatment group were treated with sedative cataplasm on Shenjue acupoint.The treatment duration was 4 weeks.The Pittsburgh Sleep Quality Index(PSQI)was used to evaluate clinical efficacy.[Results]The overall efficacy of the treatment group and control group was 91.1%and 77.1%,respectively,and the difference between the two was significant(P<0.05).After treatment,the PSQI scores of each group changed significantly(P<0.05).[Conclusions]Sedative cataplasm has a good clinical efficacy on sub-healthy insomnia patients.展开更多
Objective:To observe the effect of MJPC cataplasm on the content of epithelial-derived cytokines in lung,skin and intestine of asthmatic mice.Methods:C57/BL6 female mice were randomly divided into four groups:control ...Objective:To observe the effect of MJPC cataplasm on the content of epithelial-derived cytokines in lung,skin and intestine of asthmatic mice.Methods:C57/BL6 female mice were randomly divided into four groups:control group,asthma model group,dexamethasone group and MJPC cataplasm group.Ovalbumin sensitized and challenged asthmatic mouse models were established.The spleen index was calculated,and HE staining was used to observe the pathological change in lung tissues.The ova-specific IgE in the mouse serum and the content of TSLP in lung,skin and intestine were detected by enzyme-linked immunosorbent assay(ELISA).The expressions of TSLP mRNA and IL-33 mRNA in skin and intestinal tissue were detected by qRT-PCR.Results:Compared with the control group,the spleen index of mice in asthma model group was increased.Vascular congestion and edema,inflammatory cell infiltration and bronchial wall thickening were observed.The expressions of IgE in the mouse serum were significantly increased,and the content of TSLP in lung and skin tissue increased,but that in intestine tissue did not change significantly.The expression of TSLP mRNA was up-regulated in skin and intestinal tissues.The expression of IL-33 mRNA was up-regulated in skin tissue,but not in intestine,and the differences were statistically significant(P<0.05);Compared with the model group,MJPC cataplasm could decrease the spleen index and the expression of IgE in the mouse serum,improve the pathological damage of lung tissue in asthmatic mice,reduce the content of TSLP in lung,skin and intestinal tissue,increased the expression of TSLP mRNA in skin tissue,and down-regulate the expression of Il-33 mRNA in skin tissue and the expression of TSLP mRNA and IL-33 mRNA expression in intestinal tissue(P<0.05).Pearson correlation coefficient(r)of the content of TSLP between lung and skin was 0.689,that between lung and intestinal was-0.163,and that between skin and intestinal was-0.163,and the differences were not statistically significant(P>0.05).Conclusion:MJPC cataplasm improve airway inflammation by inhibiting the content of epithelial-derived cytokines on the"lung-skin-intestine"axis of asthmatic mice,and achieve the effect of treating asthm.展开更多
Background:Clinical trial evidence is limited to identify better topical non-steroidal anti-inflammatory drugs(NSAIDs)for treating knee osteoarthritis(OA).We aimed to compare the clinical efficacy and safety of flurbi...Background:Clinical trial evidence is limited to identify better topical non-steroidal anti-inflammatory drugs(NSAIDs)for treating knee osteoarthritis(OA).We aimed to compare the clinical efficacy and safety of flurbiprofen cataplasms(FPC)with loxoprofen sodium cataplasms(LSC)in treating patients with knee OA.Methods:This is an open-label,non-inferiority randomized controlled trial conducted at Peking University Shougang Hospital.Overall,250 patients with knee OA admitted from October 2021 to April 2022 were randomly assigned to FPC and LSC treatment groups in a 1:1 ratio.Both medications were administered to patients for 28 days.The primary outcome was the change of pain measured by visual analog scale(VAS)score from baseline to day 28(range,0-10 points;higher score indicates worse pain;non-inferiority margin:1 point;superiority margin:0 point).There were four secondary outcomes,including the extent of pain relief,the change trends of VAS scores,joint function scores measured by the Western Ontario and McMaster University Osteoarthritis Index(WOMAC),and adverse events.Results:Among 250 randomized patients(One patient without complete baseline record in the flurbiprofen cataplasms was excluded;age,62.8±10.5 years;61.4%[153/249]women),234(93.6%)finally completed the trial.In the intention-to-treat analysis,the decline of the VAS score for the 24-h most intense pain in the FPC group was non-inferior,and also superior to that in the LSC group(differences and 95%confidence interval,0.414(0.147-0.681);P<0.001 for non-inferiority;P=0.001 for superiority).Similar results were observed of the VAS scores for the current pain and pain during exercise.WOMAC scores were also lower in the FPC group at week 4(12.50[8.00-22.50]vs.16.00[11.00-27.00],P=0.010),mainly driven by the dimension of daily activity difficulty.In addition,the FPC group experienced a significantly lower incidence of adverse events(5.6%[7/124]vs.33.6%[42/125],P<0.001),including irritation,rash and pain of the skin,and sticky hair uncovering pain.Conclusions:This study suggested that FPC is superior to LSC for treating patients with knee OA in pain relief,joint function improvement,and safety profile.Trial Registration:ChiCTR.org.cn,ChiCTR2100054822.展开更多
目的:运用网络药理学联合分子对接技术探讨消定膏巴布剂治疗膝关节慢性滑膜炎的分子机制。方法:使用中药系统药理学数据库与分析平台(TCMSP)筛选消定膏巴布剂的有效成分和靶标,检索TTD、GeneCards等疾病基因数据库,获得慢性滑膜炎相关...目的:运用网络药理学联合分子对接技术探讨消定膏巴布剂治疗膝关节慢性滑膜炎的分子机制。方法:使用中药系统药理学数据库与分析平台(TCMSP)筛选消定膏巴布剂的有效成分和靶标,检索TTD、GeneCards等疾病基因数据库,获得慢性滑膜炎相关疾病基因,与药物靶标取交集得到消定膏巴布剂治疗慢性滑膜炎的靶标基因。利用Cytoscape_v3.7.2构建网络调控图,通过STRING数据平台构建蛋白质-蛋白质相互作用网络并使用Cytoscape软件筛选核心基因靶标;运行R语言程序进行基因本体论(GO)功能分析与京都基因与基因组百科全书(KEGG)通路富集分析,最后利用AutoDock与PYMOL软件完成分子对接。结果:筛选获得消定膏巴布剂中有效成分82种,相关靶标203个;与慢性滑膜炎相关靶标取交集后得到67个治疗靶标。GO功能分析显示消定膏巴布剂主要涉及细胞对化学应激与氧化应激的反应等生物过程,参与膜区及膜微区等分子组成,对细胞因子受体结合及受体-配体活性等分子功能产生影响;KEGG通路分析表明消定膏巴布剂主要通过晚期糖基化终末产物(Advanced Glycation End Products,AGE)-晚期糖基化终末产物受体(Advanced Glycation End Product Receptor,RAGE)等信号通路起到抗炎镇痛的效果;分子对接显示消定膏巴布剂中槲皮素及鞣花酸等核心成分与慢性滑膜炎关键靶标结合紧密。结论:通过网络药理学研究发现消定膏巴布剂治疗膝关节慢性滑膜炎主要通过多靶标、多成分和多通路起到抗炎镇痛的作用,初步阐释了消定膏巴布剂治疗膝关节慢性滑膜炎的作用机制。展开更多
基金Science and Technology Research and Development Project of Shiyan City(16Y76).
文摘[Objectives]This study aimed to observe the clinical efficacy of sedative cataplasm in the treatment of insomnia patients with sub-health.[Methods]A total of 90 insomnia patients with sub-health were randomly and evenly divided into treatment group and control group.The patients in the control group were given Bozi Yangxin pills orally,and those in the treatment group were treated with sedative cataplasm on Shenjue acupoint.The treatment duration was 4 weeks.The Pittsburgh Sleep Quality Index(PSQI)was used to evaluate clinical efficacy.[Results]The overall efficacy of the treatment group and control group was 91.1%and 77.1%,respectively,and the difference between the two was significant(P<0.05).After treatment,the PSQI scores of each group changed significantly(P<0.05).[Conclusions]Sedative cataplasm has a good clinical efficacy on sub-healthy insomnia patients.
基金National Natural Science Foundation of China(No.81874448)。
文摘Objective:To observe the effect of MJPC cataplasm on the content of epithelial-derived cytokines in lung,skin and intestine of asthmatic mice.Methods:C57/BL6 female mice were randomly divided into four groups:control group,asthma model group,dexamethasone group and MJPC cataplasm group.Ovalbumin sensitized and challenged asthmatic mouse models were established.The spleen index was calculated,and HE staining was used to observe the pathological change in lung tissues.The ova-specific IgE in the mouse serum and the content of TSLP in lung,skin and intestine were detected by enzyme-linked immunosorbent assay(ELISA).The expressions of TSLP mRNA and IL-33 mRNA in skin and intestinal tissue were detected by qRT-PCR.Results:Compared with the control group,the spleen index of mice in asthma model group was increased.Vascular congestion and edema,inflammatory cell infiltration and bronchial wall thickening were observed.The expressions of IgE in the mouse serum were significantly increased,and the content of TSLP in lung and skin tissue increased,but that in intestine tissue did not change significantly.The expression of TSLP mRNA was up-regulated in skin and intestinal tissues.The expression of IL-33 mRNA was up-regulated in skin tissue,but not in intestine,and the differences were statistically significant(P<0.05);Compared with the model group,MJPC cataplasm could decrease the spleen index and the expression of IgE in the mouse serum,improve the pathological damage of lung tissue in asthmatic mice,reduce the content of TSLP in lung,skin and intestinal tissue,increased the expression of TSLP mRNA in skin tissue,and down-regulate the expression of Il-33 mRNA in skin tissue and the expression of TSLP mRNA and IL-33 mRNA expression in intestinal tissue(P<0.05).Pearson correlation coefficient(r)of the content of TSLP between lung and skin was 0.689,that between lung and intestinal was-0.163,and that between skin and intestinal was-0.163,and the differences were not statistically significant(P>0.05).Conclusion:MJPC cataplasm improve airway inflammation by inhibiting the content of epithelial-derived cytokines on the"lung-skin-intestine"axis of asthmatic mice,and achieve the effect of treating asthm.
文摘Background:Clinical trial evidence is limited to identify better topical non-steroidal anti-inflammatory drugs(NSAIDs)for treating knee osteoarthritis(OA).We aimed to compare the clinical efficacy and safety of flurbiprofen cataplasms(FPC)with loxoprofen sodium cataplasms(LSC)in treating patients with knee OA.Methods:This is an open-label,non-inferiority randomized controlled trial conducted at Peking University Shougang Hospital.Overall,250 patients with knee OA admitted from October 2021 to April 2022 were randomly assigned to FPC and LSC treatment groups in a 1:1 ratio.Both medications were administered to patients for 28 days.The primary outcome was the change of pain measured by visual analog scale(VAS)score from baseline to day 28(range,0-10 points;higher score indicates worse pain;non-inferiority margin:1 point;superiority margin:0 point).There were four secondary outcomes,including the extent of pain relief,the change trends of VAS scores,joint function scores measured by the Western Ontario and McMaster University Osteoarthritis Index(WOMAC),and adverse events.Results:Among 250 randomized patients(One patient without complete baseline record in the flurbiprofen cataplasms was excluded;age,62.8±10.5 years;61.4%[153/249]women),234(93.6%)finally completed the trial.In the intention-to-treat analysis,the decline of the VAS score for the 24-h most intense pain in the FPC group was non-inferior,and also superior to that in the LSC group(differences and 95%confidence interval,0.414(0.147-0.681);P<0.001 for non-inferiority;P=0.001 for superiority).Similar results were observed of the VAS scores for the current pain and pain during exercise.WOMAC scores were also lower in the FPC group at week 4(12.50[8.00-22.50]vs.16.00[11.00-27.00],P=0.010),mainly driven by the dimension of daily activity difficulty.In addition,the FPC group experienced a significantly lower incidence of adverse events(5.6%[7/124]vs.33.6%[42/125],P<0.001),including irritation,rash and pain of the skin,and sticky hair uncovering pain.Conclusions:This study suggested that FPC is superior to LSC for treating patients with knee OA in pain relief,joint function improvement,and safety profile.Trial Registration:ChiCTR.org.cn,ChiCTR2100054822.
文摘目的:运用网络药理学联合分子对接技术探讨消定膏巴布剂治疗膝关节慢性滑膜炎的分子机制。方法:使用中药系统药理学数据库与分析平台(TCMSP)筛选消定膏巴布剂的有效成分和靶标,检索TTD、GeneCards等疾病基因数据库,获得慢性滑膜炎相关疾病基因,与药物靶标取交集得到消定膏巴布剂治疗慢性滑膜炎的靶标基因。利用Cytoscape_v3.7.2构建网络调控图,通过STRING数据平台构建蛋白质-蛋白质相互作用网络并使用Cytoscape软件筛选核心基因靶标;运行R语言程序进行基因本体论(GO)功能分析与京都基因与基因组百科全书(KEGG)通路富集分析,最后利用AutoDock与PYMOL软件完成分子对接。结果:筛选获得消定膏巴布剂中有效成分82种,相关靶标203个;与慢性滑膜炎相关靶标取交集后得到67个治疗靶标。GO功能分析显示消定膏巴布剂主要涉及细胞对化学应激与氧化应激的反应等生物过程,参与膜区及膜微区等分子组成,对细胞因子受体结合及受体-配体活性等分子功能产生影响;KEGG通路分析表明消定膏巴布剂主要通过晚期糖基化终末产物(Advanced Glycation End Products,AGE)-晚期糖基化终末产物受体(Advanced Glycation End Product Receptor,RAGE)等信号通路起到抗炎镇痛的效果;分子对接显示消定膏巴布剂中槲皮素及鞣花酸等核心成分与慢性滑膜炎关键靶标结合紧密。结论:通过网络药理学研究发现消定膏巴布剂治疗膝关节慢性滑膜炎主要通过多靶标、多成分和多通路起到抗炎镇痛的作用,初步阐释了消定膏巴布剂治疗膝关节慢性滑膜炎的作用机制。
